BioSpace News Archive

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.

Berotralstat significantly reduced HAE attack rates versus placebo over 24 weeks

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies, announced that it will host a virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, to discuss the Company’s AXO-Lenti-PD gene therapy for Parkinson’s disease.

Bausch Health Companies Inc and Salix Pharmaceuticals announced 11 scientific posters presenting data that span Salix’s portfolio at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, taking place Oct. 23-28, 2020.

Concert Pharmaceuticals, Inc. announced that the Journal of Investigative Dermatology published results from a survey designed to understand the burden and everyday experience for patients living with moderate-to-severe alopecia areata.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention” on Thursday, October 29, at 10:05 A.M. Eastern Time at the 23 rd Annual BioFlorida Conference. The presentation will be webcast live on the conference event platform, which can be accessed here . The BioFlorida Confe

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that members of management will participate in the Virtual Inves

Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that management and key opinion leaders will discuss AC5 ® Advanced Wound System in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 12:00 PM ET. For the Roundtable discussion, Terrence W. Norchi, MD, Chief Executive Officer of Arch will be joined by Randall Wolc

Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announces the appointment of David Jacobs, M.D., as Chief Development Officer.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces today that it will report third quarter 2020 financial results on Wednesday, October 28, 2020 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, October 29, 2020 to review financial results and provide an